Sexual incentive motivation in male rats requires both androgens and estrogens.
In Experiment 1 castrated male rats were implanted with a Silastic capsule containing either E or cholesterol (CHOL) 35 days after castration. They were then tested for sexual incentive motivation and copulatory behaviors every 5th day for 3 weeks. None of the treatments affected sexual incentive motivation. After the last test, all subjects were implanted with DHT-containing Silastic capsules, and tests continued for another 3 weeks. While E+DHT enhanced sexual incentive motivation and copulatory behavior, DHT alone failed to do so. In Experiment 2 the aromatase inhibitor fadrozole (F) was combined with testosterone (T). T restored all behaviors to the level seen in intact rats, and F significantly reduced these effects. In fact, T+F was not different from DHT. T and DHT restored the weight of the prostate and seminal vesicles to levels close to those of intact rats. In Experiment 3 a lower dose of E was employed. Also this dose of E failed to affect sexual incentive motivation while E+DHT restored it to the level of intact animals. Castration enhanced the serum concentrations of LH and FSH. E alone caused a marked reduction, and E+DHT brought both gonadotropins back to the level of intact animals. It was concluded that the doses of E and DHT employed in these experiments were within or close to the physiological range, and that such doses of E completely fail to enhance sexual incentive motivation in castrated animals. DHT has small or no effects. It appears that sexual incentive motivation and copulation require simultaneous stimulation of androgen and estrogen receptors.
Attila
Martti
M
Orion Pharma, Department of Oncology and Critical Care Research, Turku, Finland.
Oksala
Riikka
R
Agmo
Anders
A
D000728:Androgens / Q000378:metabolism*; D000818:Animals; D047072:Aromatase Inhibitors / Q000494:pharmacology; D001835:Body Weight / Q000502:physiology; D002784:Cholesterol / Q000378:metabolism; D003307:Copulation / Q000187:drug effects / Q000502:physiology; D013196:Dihydrotestosterone / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D017316:Fadrozole / Q000494:pharmacology; D005640:Follicle Stimulating Hormone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009042:Motivation / Q000187:drug effects / Q000502:physiology*; D009919:Orchiectomy; D009929:Organ Size; D011467:Prostate / Q000473:pathology / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012669:Seminal Vesicles / Q000473:pathology / Q000502:physiology; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D013739:Testosterone / Q000378:metabolism
D000728:Androgens; D047072:Aromatase Inhibitors; D004967:Estrogens; D013196:Dihydrotestosterone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002784:Cholesterol; D017316:Fadrozole